Hematology NewsArmored CAR protects T cells, induces remissionsJanuary 4, 2019Cellular TherapyImmuno-oncologyLymphoma & Plasma Cell DisordersCLLAggressive LymphomasImmunotherapyB Cell Lymphoma
Hematology NewsLong-term side effects of CAR T cells mostly mildJanuary 4, 2019Cellular TherapyCLLAggressive LymphomasImmunotherapyB Cell Lymphoma
Hematology TimesGroup proposes new grading systems for CRS, neurotoxicityJanuary 3, 2019Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaTransplantationALLNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesRisk of second cancers in Hodgkin lymphoma survivorsDecember 27, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Hematology NewsCheckmate 436: Two-drug combo is ‘promising’ for PMBCLDecember 21, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsECHELON-2: BV-CHP boosts survival in PTCLDecember 20, 2018T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology TimesCHMP recommends BV+AVD for Hodgkin lymphomaDecember 18, 2018Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology TimesCombo bests standard care in younger CLL patientsDecember 12, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsIbrutinib-rituximab ‘new standard of care’ in younger CLL patientsDecember 11, 2018CLLLeukemia, Myelodysplasia, TransplantationAggressive Lymphomas
Hematology TimesMutation confers resistance to venetoclax in CLLDecember 7, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology TimesTwo-drug combo deemed ‘very promising’ for PMBCLDecember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology News2018: A banner year for hematology drug approvalsDecember 5, 2018Business of MedicineCLLAggressive LymphomasMixed TopicsPractice ManagementLymphoma & Plasma Cell DisordersRare Diseases
Oncology PracticePhase 3 study confirms biosimilarity of PF-05280586 with rituximabDecember 5, 2018Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsCLL resistance mechanism to venetoclax identifiedDecember 5, 2018CLLAggressive LymphomasLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsShorter R-CHOP regimen noninferior in certain DLBCL patientsDecember 5, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
